Once the experimental and control treatments were allocated, the surgeon filled the intra-bony lesion with either a frozen, radiation sterilized, allogenic, bone granules (FRSABG) in the test sites, or deproteinized bovine bone mineral granules (DBBM (Bio-Oss®, Geistlich Biomaterials, Princeton, NJ, USA) in the control sites. Patients were blind to the treatment mode. In both sites, a porcine-derived bioabsorbable collagen membrane (Bio-Gide®, Geistlich Biomaterials) was trimmed, closely filling the bone replacement graft and adapted to the anatomy of the defect. Flaps were then coronally repositioned without any tension (periosteum was released when necessary) to fully cover the regenerated site and secured with a combination of horizontal mattress sutures (Seralon 5/0 15 mm 3/8, Serag-Wiessner GmbH & Co., Naila, Germany) and a single vertical mattress suture positioned vertically in the inter-dental areas (Seralon 6/0 12 mm 3/8). Periodontal dressing was not used in any case.
Post-surgically, the patients were prescribed the use of anti-inflammatory medication (ibuprofen 600 mg twice a day for 2 days) and systemic antibiotic therapy (amoxicillin clavulanic acid (1 g) twice daily for 7 days). Patients also received postoperative instructions to avoid brushing or chewing for two weeks and to use an antiseptic rinse (0.2% chlorhexidine) for 3 weeks. Sutures were removed at 2 weeks when patients resumed careful brushing with a soft toothbrush. Patients were recalled every 2 weeks during the first 3 months postoperatively, and every 3 months for 1 year afterward.